Amicus Therapeutics (FOLD) Stock: Buy, Sell, or Hold?
FOLD - Amicus Therapeutics, Inc
$14.49
0.03 (0.21%)
â˛
5d:
+0.21%
30d:
+0.42%
90d:
+1.51%
WAIT
LOW Confidence
Analysis Updated: Apr 24, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When FOLD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: FOLD is fairly priced but lacks strong directional signals. At -1.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: FOLD is fairly priced but lacks strong directional signals. At -1.5% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$29.50
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$18.32
20.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FOLD is currently trading at $14.49, which is considered fair based on recent price action. The stock's valuation (Forward PE: 17.7) is in line with its historical norms (18.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, FOLD is in a strong uptrend. The price is currently testing key support at $14.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, FOLD is in a strong uptrend. The price is currently testing key support at $14.45. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
52/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
62.9%
Protect Your Profits
FOLD is technically overbought (RSI 70). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- NEUTRAL: Near Wall St target ($14.50)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$14.45
Resistance Level
$14.50
Current Trend
Strong Uptrend
Technical data as of
Apr 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
17.69
Wall Street Target
$14.50
(+0.1%)
Revenue Growth (YoY)
23.7%
Earnings Growth (YoY)
-95.5%
Profit Margin
-4.3%
Valuation Discount vs History
-1.5% cheaper
PE vs Historical
17.7 vs 18.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.5%
(market-implied from PE analysis)
1-Year Target
$14.27
(-2%)
2-Year Target
$14.06
(-3%)
3-Year Target
$13.85
(-4%)
3-Yr Target (if PE normalizes)
(PE: 18â19)
$14.48
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.6, Growth: 1028.0%)
$56.96
(+293%)
Base:
(SPY PE: 17.7, Growth: 1028.0%)
$48.90
(+238%)
Bear:
(PE: 15.0, Growth: 1028.0%)
$41.57
(+187%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 17.7 to 18.5
Stabilization Target:
$15.15
(+4.6%)
PE Expansion Potential:
+4.6%
Share & Embed Analysis
Last updated: October 02, 2026 7:06 AM ET
Data refreshes hourly during market hours. Next update: 8:06 AM
Data refreshes hourly during market hours. Next update: 8:06 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FOLD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 63 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 55 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 57 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 70 BUY |
|
ARWR
Arrowhead PharmaceuticalâĻ |
STRONG BUY
13 analysts |
$107 | 68 BUY |
Advanced FOLD Option Strategies
Professional options setups generated by AI based on today's FOLD price and gamma walls.
